Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...
1 S&P 500 Stock for Long-Term Investors and 2 We Ignore
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...
1 Mid-Cap Stock with Promising Prospects and 2 We Brush Off
1 Cash-Producing Stock for Long-Term Investors and 2 We Turn Down
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Apellis Pharmaceuticals...
The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +2.91%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +2.49%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +3.43%. June E-mini...
Apellis Pharma stock more than doubled as Biogen announced a $5.6 billion acquisition. But for investors looking to jump into APLS shares now, the ship has already sailed.
The S&P 500 Index ($SPX ) (SPY ) today is up +1.02%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.67%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.10%. June E-mini S&P futures (ESM26...